These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 20194236)

  • 1. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.
    Spivak JL
    Ann Intern Med; 2010 Mar; 152(5):300-6. PubMed ID: 20194236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
    Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
    Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K; Shimoda K
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Leukemia; 2008 Jan; 22(1):194-5. PubMed ID: 17625603
    [No Abstract]   [Full Text] [Related]  

  • 13. Characterization of murine JAK2V617F-positive myeloproliferative disease.
    Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
    Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial chronic myeloproliferative disorders: the state of the art.
    Rumi E
    Hematol Oncol; 2008 Sep; 26(3):131-8. PubMed ID: 18484677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
    Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
    PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
    Garber K
    J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
    [No Abstract]   [Full Text] [Related]  

  • 17. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
    Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T
    Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.
    Stein BL; Williams DM; O'Keefe C; Rogers O; Ingersoll RG; Spivak JL; Verma A; Maciejewski JP; McDevitt MA; Moliterno AR
    Haematologica; 2011 Oct; 96(10):1462-9. PubMed ID: 21712540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.